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A B S T R A C T
Clinical and experimental observations indicate a critical role for vascular endothelial growth factor (VEGF),
secreted by the retinal pigment epithelium (RPE), in pathological angiogenesis and the development of
choroidal neovascularization (CNV) in age-related macular degeneration (AMD). RPE-mediated VEGF
expression, leading to angiogenesis, is a major signaling mechanism underlying ocular neovascular disease.
Inhibiting this signaling pathway with a therapeutic molecule is a promising anti-angiogenic strategy to treat
this disease with potentially fewer side eﬀects. Oxalomalate (OMA) is a competitive inhibitor of NADP+-
dependent isocitrate dehydrogenase (IDH), which plays an important role in cellular signaling pathways
regulated by reactive oxygen species (ROS). Here, we have investigated the inhibitory eﬀect of OMA on the
expression of VEGF, and the associated underlying mechanism of action, using in vitro and in vivo RPE cell
models of AMD. We found that OMA reduced the expression and secretion of VEGF in RPE cells, and
consequently inhibited CNV formation. This function of OMA was linked to its capacity to activate the pVHL-
mediated HIF-1α degradation in these cells, partly via a ROS-dependent ATM signaling axis, through inhibition
of IDH enzymes. These ﬁndings reveal a novel role for OMA in inhibiting RPE-derived VEGF expression and
angiogenesis, and suggest unique therapeutic strategies for treating pathological angiogenesis and AMD
development.
1. Introduction
The vascular endothelial growth factor (VEGF) family consists of a
number of closely related ligands, including VEGF-A, B, C, D, E, and
placental growth factor (PIGF) [1]. VEGF-A (hereafter referred to as
VEGF) is a critical angiogenic factor associated with several ocular
pathologies, including age-related macular degeneration (AMD) and
proliferative diabetic retinopathy [2,3]. During the pathogenesis of
AMD, increased VEGF expression leads to proliferation of pathological
and highly permeable vessels in the subretinal space, speciﬁcally
choroidal neovascularization (CNV), resulting in severe vision loss
[4–6]. In adults, retinal pigment epithelium (RPE), an epithelial
monolayer situated between the choroid and the photoreceptors,
appears to be the only source of VEGF in the back of the eye [7,8].
Various studies demonstrated that the diﬀerentiated RPE constitutively
secretes VEGF in a polarized fashion toward the basolateral side [9,10],
and that its major signaling receptor, VEGFR2, is preferentially
expressed by the choriocapillaris (CC) on the side facing the RPE
[8,9]. VEGF-VEGFR2 binding leads to the induction of various signal-
ing cascades including, MAPK, Akt, and Src, which is critical for the
proliferation of the choroidal capillary endothelial cells and the
maintenance of the fenestration of the CC [11,12]. However, upregula-
tion of VEGF by the RPE due to age-dependent or pathological
alterations is considered a critical factor in the development of CNV
in AMD [13,14].
Thus, the clear involvement of VEGF in proliferative AMD has led
to the development of multiple anti-VEGF drugs such as pegaptanib
and ranibizumab, which are approved by the Food and Drug
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Administration for the treatment of CNV [15–17]. All of these
molecules bind to secreted soluble VEGF and prevent its interaction
with VEGFR2 on the CC [18–20]. However, currently available anti-
VEGF therapeutics, for the treatment of ocular neovascular diseases, do
not alter retinal expression of VEGF. Consequently, current therapeutic
molecules are administered repeatedly at very high doses, and systemic
side eﬀects aﬀect their utility in the treatment of ocular disease [21,22].
Hence, therapeutic molecules designed to inhibit the underlying
signaling mechanisms of retinal VEGF expression appear to have
promising anti-angiogenic properties with fewer side eﬀects.
Oxalomalate (OMA, α-hydroxy-β-oxalosuccinic acid), a tricar-
boxylic acid intermediate, is a well-known potent competitive inhibitor
of two classes of NADP+-dependent isocitrate dehydrogenase isoen-
zymes, which are primarily located in either the cytoplasm (IDH1) or
mitochondria (IDH2) [23,24]. OMA can be formed in vitro and in vivo
by condensation of oxaloacetate with glyoxylate. In fact, it is produced
in vitro by a non-enzymatic aldol condensation between oxaloacetate
and the highly reactive glyoxylate [25,26]. This reaction also occurs in
vivo in mammalian cells under physiological conditions when oxaloa-
cetate and glyoxylate are present, the latter being synthesized and
catabolized in cells of vertebrates [27–29].
NADPH, a metabolic product of IDH enzymes, is required for the
regeneration of glutathione as a reducing equivalent and thus, critical
for the scavenging of cellular reactive oxygen species (ROS) by
glutathione reductase and peroxidase systems [30,31]. There is a large
body of research demonstrating the general eﬀect of oxidative stress on
signaling pathways, termed “oxidative interface”. During this process,
ROS directly interact with critical signaling molecules including MAP
kinase, PI3 kinase, Nrf-2, and ATM to initiate signaling in a variety of
cellular processes, such as proliferation, metabolism, diﬀerentiation,
and survival, indicating that ROS serve as critical signaling molecules
[32–36].
IDH enzyme isoforms, or NADPH-generating enzymes, are major
antioxidants and redox regulators that prevent oxidative stress by
catalyzing the production of NADPH within diﬀerent subcellular
compartments [37,38]. IDH enzymes are evolutionarily conserved
proteins that catalyze the oxidative decarboxylation of isocitrate to α-
ketoglutarate and the reduction of NADP+ to NADPH [39]. Speciﬁcally,
IDH2 acts as a NADP+-consuming enzyme in the forward Krebs cycle,
generating NADPH for the maintenance of reduced glutathione and
peroxiredoxin systems, and for self-maintenance via the reactivation of
cysteine-inactivated IDH2 by glutaredoxin 2 [39,40].
It was recently reported that OMA contributes to the regulation of
lipid metabolism by inhibiting lipid biosynthesis, linking cellular redox
status, and regulating adipocyte function. Studies have indicated a
decrease in IDH activity after OMA treatment, resulting in reduced
plasma triglyceride and cholesterol levels and adipocyte lipoprotein
lipase activity, suggesting a possible inhibitory role of OMA in fat
accumulation [41]. Apart from its lipid-lowering eﬀects, OMA has
several other eﬀects, such as enhanced apoptotic cell death in cancer
cells, and an inhibitory eﬀect on the LPS-induced inﬂammatory
response through the induction of intracellular ROS accumulation
[42–45]. However, to the best of our knowledge, there is no informa-
tion available regarding the eﬀects of OMA on CNV in AMD.
Researchers have focused on the association between soluble VEGF
and neovascular disease [18–20], but not on VEGF expression. Thus, in
the present study, we examined the activity of OMA using in vitro and
in vivo RPE cell models of AMD. The aim was determine whether OMA
acts on RPE cells to modulate the expression and secretion of VEGF,
thus altering the function of the retinal epithelial cells. This could
represent a potential therapeutic approach to treat pathological
angiogenesis and CNV development in age-related macular degenera-
tion.
2. Materials and methods
2.1. Cell culture
RPE cells (CRL-4000) and human umbilical vein endothelial cells
(Hereafter referred to as HUVECs; CRL-1730) were purchased from
ATCC. The RPE cells were cultured in 37 °C, 5% CO2 saturated
humidity incubator with DMEM containing 1% penicillin-streptomycin
and 10% FBS. Cells in the control group were treated as follows: the
cells were cultured in the medium for 24 h, followed by culture in the
medium containing 5 mM OMA (Cayman Chemical) for 24 h. Cell
culture was conducted in 37 °C and 5% CO2 saturated humidity
incubator. Conditioned media (CM) from the RPE cells were estab-
lished as follows: the cells were grown to 60–70% cell density in serum-
free DMEM for 24 h, and the medium was then changed to the medium
containing 5 mM OMA. Following culture for 24 h, the medium was
replaced with new serum-free DMEM and culture was continued for
24 h. The culture supernatants were then harvested and centrifuged at
300g at 4 °C for 5 min to eliminate the intact cells after which they were
concentrated and desalted by centrifugation in Amicon Ultra-15 tubes
(5 kDa molecular weight cutoﬀ; Millipore). The HUVECs were culture
in a 37 °C, 5% CO2 saturated humidity incubator with extracellular
matrix (ECM) medium supplemented with 1% penicillin-streptomycin
and 10% FBS. The HUVECs were cultured with CM that was collected
following the exposure of the RPE cells to OMA, and the control cells
were cultured in serum-free DMEM.
2.2. Cell proliferation assay
Cell proliferation was assessed by MTT assay according to the
manufacturer's recommendations (Roche). Brieﬂy, RPE cells were
seeded in a 96-well culture plate with 1×104 cells/well, and the
following day, the cells were treated as described above. Following
culture for 24 h, the culture medium was removed and 100 μl MTT
solution were added, followed by incubation for 4 h in an incubator at
37 °C; the MTT solution was then removed and 100 μl DMSO were
added to each well, followed by mixing for 10 min, and the OD value
was then measured at 540nm using a Ultrospec 2100-pro spectro-
photometer (Amersham Biosciences). Proliferation of HUVECs was
assessed as follows: the cells were treated as described above. Then, the
cells were washed with PBS twice, ﬁxed for 20 min in 3:1 methanol:
acetic acid, rinsed with water, stained with 5% crystal violet or 1 μg/mL
propidium iodide, and counted. Cell proliferation was calculated from
the ratio of the number of cells in the treated samples to those in the
control plates.
2.2.1. In vitro cell migration assay
In vitro, the scratch-wound assay was used to detect the migration
of HUVECs, as described previously [46]. HUVECs were grown to 80–
90% conﬂuence in 12-well plates in serum-free DMEM. Plates were
mechanically scratched with a sterile 10 μl pipette tip to create two
perpendicular linear scrapes. The cells were extensively rinsed with
phosphate-buﬀered saline (PBS) to remove cellular debris before
treating with CM in the serum-deprived condition to determine the
contribution of cell proliferation to the wound healing. The progression
of migration was photographed immediately and 24 h after wounding
in the same ﬁeld, near the crossing point, using digital camera (Nikon)
connected to a Zeiss Axiovert 200 inverted microscope. Extent of
wound healing was determined by the distance traversed by cells
migrating into the denuded area. The horizontal lines indicate the
wound edge. Migration of HUVECs across the wound margins from
24 h was assessed and photographed by inverted microscopy. Original
wound area width- Wound area width of 24 h after injury=Recovered
area width (% of the control recovered are width). Recovered area
width is means that HUVEC cell migration distance or Wound closure
rate is (Wound area0 h−Wound area24 h)×100/Wound area0 h.
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Representative data is cumulative of three independent experiments.
2.2.2. In vitro angiogenesis assay
The cells were plated with Matrigel (BD Biosciences), and the
HUVECs were stimulated to form capillary tube-like structure, as
previously described [47]. Matrigel (60 μl) was added to a well of a
96-well plate, and the culture plate was shaken gently. Following
Matrigel solidiﬁcation, a 100 μl suspension of HUVECs was added to
each well at a cell density of 1×104. The cells were then treated with
CM, and cultured in a 37 °C, 5% CO2 incubator for 24 h. For
ﬂuorescent monitoring of tube formation, prior to harvesting,
HUVECs were incubated for 30 min with 2 µM Calcein AM (BD
Biosciences) at 37 °C. The cells were harvested and counted, and a
single cell suspension at 1×106 cells/mL was prepared. The cells were
diluted in serum-free DMDM in the presence of CM. The cells were
added at a density of 1×104 per 100 μl to each well and incubated for
24 h in a CO2 incubator at 37 °C. The tube formation was visualized
directly through a Zeiss Axiovert 200 inverted microscope, and phase
contrast photomicrographs were acquired. Wherever Calcein AM was
used during assay, tube formation was visualized by using a Zeiss
ﬂuorescence Axiovert 40 CFL inverted microscope (485 nm excitation/
520 nm emission). To analyze angiogenic activity after treatment with
respective substances, the extent of tube formation in each cell
population was quantiﬁed by measuring the cumulative tube length
with ImageQuant 5.2 software (Molecular Dynamics).
2.3. ELISA assay
Secreted VEGF concentrations were measured using commercially
available enzyme-linked immunosorbent assay (ELISA) kits according
to the manufacturer's instructions (R &D Systems). Volumes of CM
were normalized to the total number of cells present at the time of
collection.
2.4. RT-PCR
Total RNA was extracted from cultured cell using an RNeasy Mini
Kit according to the manufacturer's instructions (Qiagen). Purity of the
RNA samples was assessed by determination of the optical density at
260:280 nm. Three micrograms of total RNA was used for cDNA
synthesis using GoScript Reverse Transcription System (Promega).
Sequences of the primers used were as follows: for HIF-1α, 5´
CAACCCAGACATATCCACCTC and 3´ CTCTGATCATCTG-
ACCAAAACTCA; for VEGF, 5´ GCTTGTCACATCTGCATTCAC and 3´
AGTCCAACATCACCATGCAG; for Actin, 5´ AAGTCAGTGT-
ACAGGTAAGCC and 3´ GTCCCCCAACTTGAGATGTATG. All reactions
were performed for 30 cycles with the following temperature proﬁles:
95 °C for 3 min (initiation; 30 s/cycle thereafter); 55 °C for 45 s
(annealing); and 72 °C for 45 s (extension). 10 μl of PCR products
was then separated on 2% agarose gels and bands were visualized with
ethidium bromide staining. Quantiﬁcation of PCR products was
performed with ImageQuant 5.2 software.
2.5. Immunoblot analysis
The Following commercial antibodies and reagents were used:
VEGF, HIF-1α, pVHL, phospho-Chk2, phospho-ATM, and Ubiquitin
(Cell Signaling Technology); phospho-E2F1 and Prx-SO3 (Abcam);
Prx-SO3 (AbFrontier); IDH1 and IDH2 (Sigma Aldrich); and Actin
(Santa Cruz Biotechnology). Conventional immunoblotting procedures
were used to detect the target proteins: cells were collected, washed
once in cold PBS, and then scraped in TEGN buﬀer (10 mM Tris, pH 8,
1 mM EDTA, 10% glycerol, 0.5% Nonidet P-40, 400 mM NaCl, 1 mM
DTT, 0.5 mM phenylmethylsulfonylﬂuoride, and protease inhibitor
mixture containing 1 M benzamidine, 3 mg/mL leupeptin, 100 mg/
mL bacitracin, and 1 mg/mL α2 macroglobulin) and incubated on ice
for 15 min. Lysates were then cleared by centrifugation at 20,000 g for
10 min. Total protein concentration was determined via the Bio-Rad
protein assay. Equal amounts of protein were separated on 10% SDS-
PAGE and the proteins were transferred to nitrocellulose membranes
(Bio-Rad). The membranes were then blocked for 1 h in a PBS solution
containing 5% nonfat milk powder and 0.1% Tween-20 and then
probed with primary antibody overnight in 1% milk, 0.1% Tween-20 in
PBS. After washing, membranes were incubated for 1 h with horse-
radish peroxidase-linked secondary antibody (Sigma Aldrich) in 1%
milk, 0.1% Tween-20 in PBS. Finally, after three 5-min washes in 0.1%
PBS/Tween-20, proteins were visualized by enhanced chemilumines-
cence (Amersham Biosciences). Band intensities were quantiﬁed with
ImageQuant 5.2 software.
2.6. Immunocytochemical analysis
To study the expression of VEGF, immunoﬂuorescence staining of
VEGF was performed on RPE cells. Cells were grown on coverslips for
24 h. Thereafter, cells were treated with OMA as indicated. Cells were
washed with PBS and ﬁxed with 4% paraformaldehyde, permeabilized
with 0.5% Triton X-100 in PBS, and pre-treated with blocking solution.
After ﬁxation and after blocking the non-speciﬁc binding, the coverslips
were incubated with antibodies against VEGF (Cell Signaling
Technology) at 4 °C overnight, followed by the incubation with FITC-
conjugated secondary antibodies (Vector Laboratories) for 1 h at room
temperature in the dark. After washing, cells were counterstained with
DAPI and the coverslips were mounted on DakoCytomation
Fluorescent Mounting Medium (DAKO). The preparations were ana-
lyzed with the inverted ﬂuorescence microscope. Image analysis was
performed using the ImageQuant 5.2 software.
2.7. Proteasome inhibition and immunoprecipitation
RPE cells were treated with 20 µM of MG-132 (Sigma Aldrich) in
the presence of absence of OMA as indicated and then protein stability
was assayed by conventional immunoblotting. For ubiquitination
assay, the RPE cells were washed with ice-cold PBS and lysed in buﬀer
containing 150 mM NaCl, 50 mM Tris–HCl, pH 7.4, 1% NP-40, 1 mM
NaF, 1 mM Na3VO4, and EDTA-Free Halt Protease Inhibitor Cocktail
(Thermo Scientiﬁc Pierce) for 30 min on ice. Total cell lysates (1 mg of
protein) were subjected to immunoprecipitation with 2 μg of anti-HIF-
1α for 1 h at 4 °C. Protein G Sepharose (GE Healthcare Bio-Sciences
AB) was added and incubation continued overnight at 4 °C.
Immunoprecipitated cell lysates were subjected to 10% SDS-PAGE,
and ubiquitinylated HIF-1α was detected with anti-ubiquitin antibody
(Santa Cruz Biotechnology). ImageQuant 5.2 was used for quantifying
the protein levels based on band density exhibited in the immunoblot
photographs.
2.8. Measurement of redox status and cellular ROS
The concentration of total glutathione was determined by the rate
of formation of 5-thio-2-nitrobenzoic acid at 412 nm
(ε=1.36×104 M M−1cm−1) according to the method described by
Akerboom and Sies [48]. Oxidized glutathione (GSSG) was measured
by the 5,5´-dithiobis(2-nitrobenzoic acid)-GSSG reductase recycling
assay after treating GSH with 2-vinylpryidine [49]. NADPH was
measured using the enzymatic cycling method as described previously
[50] and expressed as the ratio of NADPH to the total NADP pool.
Intracellular ATP levels were determined by using luciferin-luciferase,
as previously described [51]. Light emission was quantitated in a
Turner Designs TD 20/20 luminometer (Stratec Biomedical Systems).
Intracellular ROS production and mitochondrial membrane potential
was measured using the oxidant-sensitive ﬂuorescent probe DCFH-DA
and cationic reagent JC-1 (Molecular Probes), respectively, with FACS
analysis (BD Biosciences) [52]. Fluorescence intensity was expressed in
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arbitrary units on a logarithmic scale. Mitochondrial ROS formation
was visualized as follows: MitoSOX (Invitrogen) was added at 5 µM in
the medium and after incubation for 10 min, cells were ﬁxed with 4%
paraformaldehyde for 10 min, mounted onto glass slides with Mowiol,
and observed under the ﬂuorescence inverted microscope. Quantitation
was performed by selecting the cellular region of 20–30 cells for each
sample and measuring the intensity of the MitoSOX ﬂuorescence using
ImageQuant 5.2 software.
2.9. Mouse xenograft model
RPE cells or HUVECs at subconﬂuence were harvested, washed
with PBS, and resuspended in the serum-free medium. A total 1.5×106
cells were mixed with an equal volume of the Matrigel in the presence
or absence of the respective substances. The mixture was immediately
inoculated s.c. into both ﬂanks of 6-week-old male athymic nu/nu
mice. The animals were bred and kept under deﬁned-ﬂora pathogen-
free conditions at the Animal Facility of the University Laboratory
Animal Resources, Kyungpook National University. All experiments
were performed in accordance with the guidelines of the University
Institutional Animal Care and Use Committee. The animals were
monitored for Matrigel plug size at 2-d intervals throughout the period
of the study. The animals were sacriﬁced 14 days after the implantation
and the Matrigel plugs were carefully excised without other adjacent
tissues. The excised plugs were photographed immediately and the
specimens were subjected to immunohistochemistry analysis described
below.
2.10. Histological analysis
Specimens of Matrigel plugs were ﬁxed in 4% (w/v) paraformalde-
hyde in PBS, and processed by conventional paraﬃin-embedded
method. The paraﬃn-embedded tissue sections with thickness of
5 µm were heat-immobilized, deparaﬃnized using xylene, then rehy-
drated in a series of increasing ethanol concentrations. Antigen
retrieval was performed by incubating the sections in 10 mM sodium
citrate (pH 6.0) and heated to 90 °C for 20 min.
Immunohistochemistry was performed using a VECTASTAIN ABC
Kit (Vector Laboratories), according to the manufacturer's instructions,
using antibody against PECAM, VWF, and ERG (Santa Cruz
Biotechnology), phospho-E2F1 (Abcam), and pVHL, HIF-1α, VEGF,
phospho-Chk2, and phospho-ATM (Cell Signaling Technology).
Histological studies of mouse eyes were performed according to
previously published protocols [53]. Eyes from each group were
enucleated, ﬁxed in 4% paraformaldehyde, and embedded in a
composite paraﬃn block. Then, the 5-μm-thick tissue sections were
deparaﬃnized, rehydrated, and used for hematoxylin and eosin stain-
ing and immunoﬂuorescence. Antibody used to identify the RPE cells
was anti-cytokeratin 18 (Santa Cruz Biotechnology). The sections were
counterstained with DAPI (Vector Laboratories). Images were acquired
with a Zeiss Axiovert 200 inverted microscope or a Zeiss LSM 510 laser
scanning confocal microscope. Staining intensities were analyzed using
color deconvolution feature of ImageQuant 5.2 software (Molecular
Dynamics).
2.11. CNV induction and therapeutic intervention
8-week-old male C57BL/6 J mice were used in this study. The
animals were housed in climate-controlled, speciﬁc pathogen-free
barrier facilities under a 12-h light-dark cycle, and chow and water
were provided ad libitum. The Institutional Animal Care and Use
Committee at the Kyungpook National University approved the experi-
mental protocols for this study. CNV was induced by subretinal
injection of PEG in accordance with the protocols as previously
documented [54,55]. In brief, the eye of animals was decompressed
with a 27-gauge needle by inserting the needle through the conjunctiva
and sclera 1 mm behind the limbus. A UMP3 Microinjector equipped
with a Nanoﬁl 100 μl syringe and 33-gauge blunt needle (Word
Precision Instruments) was used for injections. Needle movement
was stopped when light resistance was felt by the operator.
Subsequently, a single injection of 0.5 mg of PEG-8 (PEG with a mean
Mr of 400; Spectrum Chemical) dissolved in 2 μl of sterile PBS was then
administered in 10 s. Formation of a subretinal bleb was controlled
through observation using the microscope. Local administration of
OMA was performed by intravitreal injection, immediately following
the induction of CNV [56]. In brief, the eye was proptosed and held in
position with a pair of forceps, while 4 μg of OMA/4 μl of PBS was
injected using a 33-gauge hypodermic needle (Sigma Aldrich). The
injection site was treated with chloramphenicol and globe reposited.
The eyes were enucleated at day 3 post-injection, and subjected to
retina and RPE/choroid tissue processing for the histological analysis.
2.12. Statistical analysis
Results are shown as means ± SD, which were performed using a
two-tailed t-test.
3. Results and discussion
3.1. Eﬀect of OMA on VEGF expression and angiogenesis
To determine whether OMA can directly inhibit VEGF expression in
RPE cells, we treated these cells with OMA (5 mM) for 24 h; CM were
collected and the level of VEGF was measured by ELISA. VEGF levels
were normalized to cell numbers and those of medium volume. As
shown in Fig. 1A, OMA treatment led to a decrease in VEGF production
in RPE cells in comparison to that in control cells. Furthermore, in
agreement with the data in Fig. 1A, we also found a signiﬁcant
reduction of VEGF protein in RPE cells treated with OMA, compared
to that in control cells (Fig. 1B and C), indicating that OMA treatment
clearly reduces VEGF expression and secretion. To determine if
reduced VEGF expression occurred at the mRNA level, RT-PCR was
used to assess VEGF mRNA expression. As shown in Fig. 1D, we
observed a signiﬁcant reduction in VEGF mRNA in OMA-treated RPE
cells compared to that in control cells, indicating that OMA could
inhibit VEGF transcription. To exclude the possibility that the decrease
in VEGF production was due to inhibition of cell proliferation, we
analyzed cell proliferation using an MTT assay, under the same
experimental conditions. OMA treatment had little eﬀect on the
proliferation of RPE cells, when compared to that of control cells (data
not shown). These results suggest that the inhibition of VEGF produc-
tion by OMA was not through modulation of cell proliferation or death.
Collectively, these results suggest that OMA reduces VEGF production
through inhibition of expression at the transcriptional level.
Angiogenesis involves multiple events in endothelial cells, including
cell proliferation, migration, and tube formation, and VEGF plays a
central role in these processes. Endothelial cells respond to VEGF with
mitogenesis, followed by the organization of cells into new vessels
[57,58]. To determine the anti-angiogenic potential of OMA, and its
potential mechanism of action through VEGF inhibition, in vitro
angiogenesis assays measuring proliferation, transmigration, and tube
formation were performed in HUVECs. RPE cells were cultured with or
without OMA (5 mM) for 24 h, and CM were applied to HUVECs in a
series of angiogenic assays.
Initial experiments were performed to evaluate endothelial prolif-
eration by counting total number of HUVECs after crystal violet
staining. We found that proliferation increased after stimulation with
CM derived from RPE cells, but was signiﬁcantly inhibited when
HUVECs were cultured in CM prepared from OMA-treated RPE cells
(Fig. 1E). To further assess OMA's anti-angiogenic activity, which was
suggested by the downregulation of VEGF, motility and tube formation
assays were performed using HUVECs. As shown in Fig. 1F and G,
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OMA inhibited migration and tube formation in HUVECs induced by
CM prepared from RPE cells. The eﬀects of OMA on angiogenesis-
associated endothelial cell functions observed in vitro were conﬁrmed
in vivo in the Matrigel angiogenesis assay. Immunodeﬁcient mice were
subcutaneously injected with Matrigel suspensions containing
HUVECs treated with CM derived from either untreated or OMA-
treated RPE cells. As seen in Fig. 1H, neovascularization was observed
in HUVECs stimulated with CM from untreated RPE cells. However,
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Fig. 1. OMA inhibits VEGF expression and angiogenesis. (A) The levels of VEGF in CM of RPE cells. The data were expressed as a percentage of control treated with PBS. (B)
Immunoblot analysis of intracellular expression of VEGF in the RPE cells. Actin was used as a loading control. Quantiﬁcations of the levels of VEGF normalized to actin are shown. (C)
Representative images of immunoﬂuorescence staining of VEGF in the RPE cells. Histograms represent the quantiﬁcation of ﬂuorescence intensity. Nuclei were counterstained with
DAPI. (D) RT-PCR analysis of mRNA levels of VEGF in the RPE cells. Actin was used as an internal control for the experiment. The mRNA levels were normalized to the actin level. (E)
Cell proliferation assay for HUVECs incubated with CM for 24 h. Cells were then stained with 5% crystal violet or propidium iodide (PI) and scored. Data are represented as a ratio to
control treated with CM prepared from PBS-treated RPE cells. (F) Representative images of migration of HUVECs cultured for 24 h in the presence of CM. Extent of the cell migration
distance was calculated as described in Materials and Methods. Changes in the extent of the transmigration distance were represented as a percentage of the control group. (G)
Morphological appearance and capillary tube formation of HUVECs in the presence of CM grown on Matrigel for 24 h as shown in bright ﬁeld and ﬂuorescence micrograph of Calcein
AM-stained HUVECs, respectively. Quantitative image analysis depicting the total tube length of angiogenic structure as a percentage of control. (H) Macroscopic appearance of
neovascularization and immunohistochemical staining of angiogenesis markers in Matrigel plugs from HUVECs treated with CM. Quantitative results of blood vessel density and
expression levels of the angiogenic markers are shown as a percent of control. Each value represents the mean ± SD from three independent experiments. *P< 0.01, versus control group.
The ﬁgure shows representative data for three independent experiments.
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this eﬀect was prevented when HUVECs were treated with CM derived
from OMA-treated RPE cells. Taken together, these results suggest that
OMA possesses potent anti-angiogenic activity.
3.2. Eﬀect of OMA on HIF-1α protein expression
To explore the possible mechanism of VEGF inhibition by OMA, we
determined whether OMA could modulate the levels of HIF-1α, a
major regulator of VEGF expression. The regulation of VEGF is
mediated primarily through the transcription factor HIF-1α [3]. We
treated RPE cells with OMA and then examined the eﬀect on HIF-1α
protein levels. As shown in Fig. 2A, we found that HIF-1α expression in
RPE cells was suppressed by OMA treatment. To address whether HIF-
1α is involved in the regulation of VEGF expression in the RPE cells, we
performed RNA interference of HIF-1α using siRNA; VEGF expression
was signiﬁcantly reduced in cells transfected with siRNA against HIF-
1α but not in the cells transfected with control siRNA (data not shown).
We next asked whether inhibition of HIF-1α protein accumulation
by OMA could be a result in transcriptional inhibition. However, RT-
PCR showed no signiﬁcant changes in HIF-1α mRNA levels in RPE
cells after OMA treatment (Fig. 2B). These results suggest that OMA
suppresses HIF-1α protein accumulation probably through a post-
transcriptional mechanism. One possible post-transcriptional mechan-
ism for the inhibitory activity of OMA is increased degradation and/or
reduced synthesis of HIF-1α protein. To determine the point at which
OMA interferes with inhibition of HIF-1α protein expression, we
examined the accumulation of HIF-1α in RPE cells after treatment
with a proteasome inhibitor, MG-132, to prevent HIF-1α degradation.
HIF-1α rapidly accumulated over a period of 2 h in the presence of
MG-132. Of particular interest, the accumulation rates of HIF-1α in the
presence or absence of OMA appeared comparable (Fig. 2C), strongly
suggesting that the inhibitory eﬀect of OMA on VEGF and HIF-1α
protein expression is mediated primarily through directly promoting
HIF-1α degradation, not by suppressing the synthesis of HIF-1α.
Next, we wished to understand how HIF-1α protein degradation is
promoted in the presence of OMA. It is well established that the pVHL
tumor suppressor plays a critical role in the regulation of HIF-1α
stability, via ubiquitination and proteosomal degradation through E3
ubiquitin ligase activity [59,60]. In addition, pVHL mutations prevent
its interaction with HIF-1α, which accumulates and stimulates the
expression of several genes encoding growth factors such as VEGF that
are responsible for neovascularization [61,62]. Hence, pVHL is an
important tumor suppressor that inhibits the growth of angiogenic
tumors, mainly by depressing HIF-1α-mediated VEGF expression in
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Fig. 2. OMA promotes degradation of HIF-1α by pVHL-mediated ubiquitination. (A) Immunoblot analysis of HIF-1α levels in the RPE cells after OMA treatment. Actin served as a
loading control. The proteins levels were normalized to the actin level. (B) Quantitative RT-PCR analysis of mRNA expression of HIF-1α gene in the RPE cells. Actin was examined as a
loading control, and a graph depicting the quantiﬁcation of the relative abundance of the gene is shown. N.S. indicates no signiﬁcant diﬀerence compared to control. (C) Decay kinetics of
HIF-1α. For immunoblots of HIF-1α, the RPE cells were treated with 20 µM of MG-132 in the presence or absence of OMA for the indicated times. Immunoblot of total actin was
included as a loading control. Relative levels of the HIF-1α protein in the immunoblot were determined by measuring the density of the HIF-1α protein band and normalized to that of
actin. The data are expressed as a ratio to control at time zero. (D) pVHL is highly induced in the RPE cells by OMA treatment. The cells were treated with 5 mM OMA and harvested 24
post-treatment, and pVHL induction was probed by immunoblotting, using actin as a loading control. Results of pVHL quantiﬁcation are normalized to the expression of actin and
shown. (E) OMA increases ubiquitination of HIF-1α by upregulation of pVHL activity. The RPE cell lysates were immunoprecipitated with anti-HIF-1α antibody, and immunoblotted
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Immunohistochemical staining for protein expression of VEGF and pVHL-mediated HIF-1α degradation on Matrigel plugs mixed with the PRE cells in the presence of 5 mM OMA.
Nuclei are stained with Harris hematoxylin. Quantitative results of the expression levels of the indicated proteins are represented as a percentage of control. The ﬁgure shows
representative data for three independent experiments. Error bars represent mean ± SD (n =3). *P < 0.01, versus control group.
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response to DNA damage or oxidative stress [60]. To examine the
contribution of OMA to pVHL activity and subsequent pVHL-mediated
ubiquitination of HIF-1α, we treated RPE cells with OMA and analyzed
the expression of pVHL (Fig. 2D) and the ubiquitination of HIF-1α
(Fig. 2E). The data revealed that OMA treatment induced upregulation
of pVHL (Fig. 2D), and importantly, increased pVHL activity was
reﬂected on the stimulation of HIF-1α ubiquitination (Fig. 2E),
suggesting that OMA promotes the degradation of HIF-1α through
pVHL-mediated ubiquitination.
As a further proof that OMA could inhibit VEGF expression by
targeting HIF-1α to pVHL-mediated destruction, Matrigel mixtures
with RPE cells in the presence or absence of OMA were subcutaneously
injected into the ﬂank region of immunodeﬁcient mice. Following this
treatment regimen, the Matrigel plugs were harvested and processed
through immunohistochemical staining with the indicated antibodies.
Fig. 2F shows that administration of OMA drastically inhibited the
expression of VEGF via activation of pVHL-mediated HIF-1α degrada-
tion compared to that in the control samples, which is in agreement
with data presented in Fig. 2E. This provides a mechanistic explanation
for the response of the retinal pigment epithelium to OMA. Thus, these
results support the conclusion that OMA suppresses VEGF expression
by intervening with pVHL-mediated activation of HIF-1α degradation.
3.3. Eﬀect of OMA on the E2F1 pathway
The data presented so far indicate that OMA upregulates pVHL
activity in the RPE cells, which is associated with inhibition of VEGF
production through HIF-1α degradation. However, this data did not
provide insight into the nature of this association. We considered the
E2F1 transcription factor as a potential candidate to establish a link
between pVHL activity and OMA because pVHL is a direct downstream
target of E2F1 [63]. In addition, recently it was reported that the
phosphorylated and active form of E2F1 is regulated in ROS-depen-
dent manner [64,65]. ROS-dependent phosphorylation of E2F1 has
previously been investigated in some detail. ATM protein kinase is
phosphorylated by cellular ROS to act as a redox sensor in cells, and
ROS-dependent phosphorylation of ATM activates the eﬀector kinase
Chk2, which in turn phosphorylates its downstream target, E2F1
[32,64,66,67].
Hence, to address whether regulation of pVHL activity is mediated
by phosphorylation and activation of the ATM-Chk2-E2F1 axis, we
tested the eﬀect of OMA on the phosphorylation of components
involved in this signaling pathway. As apparent in Fig. 3A, we found
that OMA could activate the phosphorylation of E2F1, Chk2 kinase,
and E2F1 transcription factor. Moreover, in accordance with the data
in Fig. 3A, in the Matrigel plugs derived from mice treated with OMA,
the phosphorylation of these signaling components was signiﬁcantly
elevated compared to that in control samples (Fig. 3B). This suggests
that activation of the ATM-Chk2-E2F1 signaling axis contributes, at
least in part, to the enhancing eﬀect of OMA on pVHL-mediated HIF-
1α degradation, and is reﬂected in the suppression of VEGF expression.
Next, we attempted to elucidate the mechanism through which
OMA treatment leads to an elevation of ATM kinase activation in these
signaling axes. It has been well established that coordination between
cytoplasmic and nuclear activities is vital for cellular homeostasis, and
several signaling molecules and transcription factors, such as ATM
kinase and the tumor suppressor p53, are regulated by intracellular
ROS during this intracellular communication [32,68]. OMA, a tricar-
boxylic acid (α-hydroxy-β-oxalosuccinic acid) formed in in vitro and in
vivo by condensation of oxaloacetate and glyoxylate (Supplementary
Figure 1A), is known to be a potent competitive inhibitor of NADP+-
dependent isocitrate dehydrogenase isoform 1 (IDH1) and isoform 2
(IDH2), which are localized to the cytoplasm and mitochondria,
respectively [23,24]. In particular, both IDH enzyme isoforms are the
primary NADPH producers within their respective subcellular com-
partments, and thus play a critical role in cellular redox regulation
through maintaining the NADPH-dependent GSH/GSSG ratio [37–
39]. Therefore, this strongly suggests that inhibition of IDH enzymes
by OMA modulates the cellular redox status, and is thus responsible for
the regulation of this signaling pathway. As expected, the enzymatic
activity of both IDH1 and IDH2 was signiﬁcantly inhibited by OMA
treatment in RPE cells without measureable changes in the overall
levels of IDH enzymes (Supplementary Figure 1B and C). We next
inhibited IDH activity and examined the eﬀect on the redox status of
mitochondria and intracellular ROS production; we analyzed the
mitochondrial redox (Fig. 3C), mitochondrial membrane potential
(Fig. 3D), and intracellular ROS (Fig. 3E and F) in the absence and
presence of OMA. The data revealed that inactivation of IDH enzymes
by OMA led to elevated levels of mitochondrial ROS, associated with
alteration of mitochondrial membrane potential, and an increase in
intracellular ROS levels in RPE cells. This suggests an overall increase
in cellular ROS in RPE cells after OMA treatment. Taken together, the
data in Fig. 3 indicate that inhibition of IDH enzymes by OMA,
resulting in elevated cellular ROS production, regulates the ROS-
dependent ATM-mediated E2F1 axis in RPE cells.
Fig. 3G summarizes the mechanistic ﬁndings of our study as
follows: OMA reduces the activity of IDH enzymes as a competitive
inhibitor in RPE cells, resulting in an elevation of intracellular ROS,
which leads to the activation of the E2F1 transcription factor. This
occurs via regulation of the ROS-mediated ATM-Chk2 signaling axis,
resulting from the modulation of the cellular redox status. As a result,
the activation of E2F1 leads to upregulation of pVHL activity, which in
turn inhibits VEGF production by promoting HIF-1α degradation.
These data therefore indicate a critical role for OMA in the inhibition of
VEGF-mediated angiogenesis.
3.4. Eﬀect of OMA on age-related macular degeneration with
choroidal neovascularization
Next, we determined whether inhibition of VEGF expression
through OMA in RPE cells could be used for therapeutic purposes.
RPE-derived VEGF is considered one of the key molecules for the
formation of CNV in AMD [13,14]. Hence, we reasoned that OMA
might inhibit CNV-related angiogenesis with a speciﬁc focus on
suppression of RPE-related VEGF production. We used a polyethylene
glycol (PEG)-induced mouse model of AMD [54,55] to test the eﬃcacy
of OMA in treating CNV development and retinal dysfunction. The
AMD mouse model was established in 8-week-old male C57BL/6 J
mice by subretinal injection of PEG-8 [55]. The mice subsequently
received 4 μg of OMA by intravitreal injection, immediately following
the induction of CNV formation. Following the treatment, we per-
formed a histological investigation of the paraﬃn sections from mouse
eyes. Light microscopic evaluation of the outer retina and choroidal
tissues of PEG-8-injected mice revealed distinct organizational changes
compared to control tissues (Fig. 4A). The CC, which normally forms a
continuous plexus beneath the Bruch's membrane (BrM), was replaced
by enlarged and discontinuous vessels. Moreover, the changes in the
choroidal vasculature were associated with RPE dysfunction, evidenced
by the presence of increased density of RPE cell nuclei.
However, the pathological phenotype of the RPE-BrM-CC complex,
the hallmarks of AMD pathology [69], were signiﬁcantly reduced in
these regions upon treatment with OMA (to a level comparable to that
seen in controls). In parallel with the eﬀect on the choroidal vascu-
lature, administration of OMA drastically suppressed CNV-related
angiogenesis, the hallmark of AMD [4,5], which was localized between
the two layers of cytokeratin 18-positive RPE cells in the subretinal
place. In contrast, the prominent choroidal vessels were located
exclusively within the choroid in the PEG-8-injected mice compared
that observed in controls (Fig. 4B). In vivo measurement of VEGF
expression in the RPE after OMA treatment revealed that there was a
massive decrease in VEGF-positive staining in the apical side of the
RPE, and within the choroid, compared that in PEG-8-treated mice.
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This was indicative of a favorable response to OMA treatment in the
RPE, which is the main producer of CNV-related VEGF (Fig. 4C). Thus,
results obtained from the in vivo mouse model of AMD support the
prediction based on experiments with cultured cells that OMA inhibits
CNV-related angiogenesis by suppressing RPE-mediated VEGF expres-
sion.
In conclusion, our ﬁndings demonstrate that OMA is able to reduce
the expression and secretion of VEGF in RPE cells through the
subsequent regulation of multiple mechanisms as follows: (1) modula-
tion of the intracellular ROS through inhibition of IDH enzymes; (2)
promotion of the ROS-dependent ATM-Chk2-E2F1 signaling axis; (3)
activation of pVHL-mediated HIF-1α degradation. Moreover, in light
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OMA. Data are presented as the mean ± SD of three independent experiments. *P < 0.01, versus control group. The ﬁgure shows representative data for three independent experiments.
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of the essential role for RPE-derived VEGF in CNV formation during
AMD, our data strongly support the hypothesis that OMA inhibits CNV
formation by reducing RPE-derived VEGF production, and thus
suggest the potential development of OMA for therapeutic approaches
targeting AMD pathogenesis.
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